CureVac NV Q4 2020 Earnings Call Transcript - Thomson StreetEvents

CureVac NV Q4 2020 Earnings Call Transcript

CureVac NV Q4 2020 Earnings Call Transcript - Thomson StreetEvents
CureVac NV Q4 2020 Earnings Call Transcript
Published Apr 15, 2021
16 pages (9883 words) — Published Apr 15, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CVAC.OQ earnings conference call or presentation 15-Apr-21 2:00pm GMT

  
Brief Excerpt:

...Operator Greetings, and welcome to the CureVac Fourth Quarter and Full Year 2020 Financial Results and Business Updates Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce Sarah Fakih, Head of Investor Relations. Thank you. You may begin. Sarah Fakih ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
CureVac NV
Ticker
CVAC.OQ
Time
2:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Congrats on the progress. The first question probably is for Pierre on the financials. Maybe can you provide a bit of color on the upfront payment from EU EUR 450 million? How much doses does it cover? And also on that, that the second one for Pierre is for the one -- I calculated about EUR 1.8 billion currently in the bank. How would you plan to use that cash for further development of the company? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 15, 2021 / 2:00PM, CVAC.OQ - Q4 2020 CureVac NV Earnings Call

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Got it. And the second question, maybe for Franz or Pierre. In terms of 2022, you upped the guidance for production. I guess have you been in the negotiation with governments for contracts versus 2022?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Got it. That is very helpful. And final question, maybe for Mariola on the Phase III reporting -- data reporting. I remember you guided earlier that potentially split the cases based on the -- whether original variant or the new variants. Would you clarify that? Would that still be the case when you finally report the efficacy endpoint? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 15, 2021 / 2:00PM, CVAC.OQ - Q4 2020 CureVac NV Earnings Call

Table Of Contents

CureVac NV Q3 2021 Earnings Call Summary – 2021-11-19 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary – 2021-10-12 – US$ 54.00 – Edited Brief of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript – 2021-10-12 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript – 2021-07-01 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 1-Jul-21 12:00pm GMT

CureVac NV Updates On Clinical Trial - Corporate Call Transcript – 2021-06-17 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 17-Jun-21 12:00pm GMT

CureVac N.V. - Special Call Transcript – 2021-02-05 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 5-Feb-21 3:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "CureVac NV Q4 2020 Earnings Call Transcript" Apr 15, 2021. Alacra Store. May 02, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2020-CureVac-NV-Earnings-Call-T14657784>
  
APA:
Thomson StreetEvents. (2021). CureVac NV Q4 2020 Earnings Call Transcript Apr 15, 2021. New York, NY: Alacra Store. Retrieved May 02, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2020-CureVac-NV-Earnings-Call-T14657784>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.